1287294-69-2

Upstream product

• 25602-68-0 3-oxo-8-azabicyclo[3.2.1]octane hydrochloride 
• 622-88-8 4-bromophenylhydrazine hydrochloride 
• 1287375-05-6 (7R,10S)-5-methyl-2-((3-(trifluoromethyl)phenyl)sulfonyl)-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[b]indole 
• 1416007-23-2 11-tert-butyl 5-(2-isopropyl-5-methylcyclohexyl) 2-bromo-7,8,9,10-tetrahydro-7,10-epiminocyclohepta[b]indole-5,11(6H)-dicarboxylate 
• 1416007-18-5 (7R,10S)-11-tert-butyl 5-((1S,2R,5S)-2-isopropyl-5-methylcyclohexyl) 2-bromo-7,8,9,10-tetrahydro-7,10-epiminocyclohepta[b]indole-5,11(6H)-dicarboxylate 

Relevant academic research and scientific papers

An efficient synthesis of (7S,10R)-2-bromo-5,6,7,8,9,10-hexahydro-7,10- epiminocyclohepta[b]indole: Application in the preparation and structural confirmation of a potent 5-HT6 antagonist

(7S,10R)-5-Methyl-2-((3-(trifluoromethyl)phenyl)sulfonyl)-5,6,7,8,9, 10-hexahydro-7,10-epiminocyclohepta[b]indole 1a is a potent 5-HT6 antagonist (h5-HT6 Ki = 1.5 nM) which is derived from an epiminocyclohept[b]indole scaf

EPIMINOCYCLOALKYL(B)INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF

The present invention relates to epiminocycloalkyl[b]indole derivatives as serotonin sub-type 6 (5-HT6) modulators, pharmaceutical compositions including these compounds, and methods of preparation and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, and schizophrenia. The subject compounds have the structure of formula (I), with the substituents being described herein.